Research ArticleClinical Sciences
Human Pharmacokinetics of Samarium-153 EDTMP in Metastatic Cancer
Amolak Singh, Richard A. Holmes, Medhi Farhangi, Wynn A. Volkert, Andrew Williams, Lynn M. Stringham and Alan R. Ketring
Journal of Nuclear Medicine November 1989, 30 (11) 1814-1818;
Amolak Singh
Richard A. Holmes
Medhi Farhangi
Wynn A. Volkert
Andrew Williams
Lynn M. Stringham


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Human Pharmacokinetics of Samarium-153 EDTMP in Metastatic Cancer
Amolak Singh, Richard A. Holmes, Medhi Farhangi, Wynn A. Volkert, Andrew Williams, Lynn M. Stringham, Alan R. Ketring
Journal of Nuclear Medicine Nov 1989, 30 (11) 1814-1818;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer
- Tumor Dosimetry and Response for 153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma
- Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis
- Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma
- Bone-Seeking Radionuclides For Therapy
- Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases
- High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases
- Therapy of Metastatic Bone Pain
- Metal compounds in therapy and diagnosis